PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA

• Christopher J. Ferreri,
• Steven Quatela,
• Oluwaseun Aina,
• Pourab Roy,
• Anita Boyapati,
• Karen Rodriguez Lorenc,
• Glenn Kroog,
• Robert Z Orlowski

Affiliations

Christopher J. Ferreri

1 The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Steven Quatela

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Oluwaseun Aina

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Pourab Roy

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Anita Boyapati

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Karen Rodriguez Lorenc

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Glenn Kroog

2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Robert Z Orlowski

1 The University of Texas MD Anderson Cancer Center, Houston, TX, United States